VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a… Read More
SAN DIEGO, June 1, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that… Read More
SEATTLE, June 01, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Erin Lavelle to the company’s Board of… Read More
VANCOUVER, British Columbia, May 27, 2020 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company, announced it has executed an option agreement with an undisclosed publicly traded company for exclusive rights to BOLD-100 in South… Read More
Potential for voclosporin to become the first FDA-approved therapy for the treatment of lupus nephritis – NDA Application supported by extensive global clinical program including the pivotal Phase 3 AURORA… Read More
